CN103356626A - Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases - Google Patents
Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases Download PDFInfo
- Publication number
- CN103356626A CN103356626A CN2013103325246A CN201310332524A CN103356626A CN 103356626 A CN103356626 A CN 103356626A CN 2013103325246 A CN2013103325246 A CN 2013103325246A CN 201310332524 A CN201310332524 A CN 201310332524A CN 103356626 A CN103356626 A CN 103356626A
- Authority
- CN
- China
- Prior art keywords
- pyrazolopyrimidine compound
- treatment
- trichophyton rubrum
- chemical compound
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention relates to a use of a pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases. The pyrazolopyrimidine compound is N3-(4-fluoropentyl)-1H-pyrazolo[3,4-D]pyrimidine-3,4-diamine. The pyrazolopyrimidine compound has good activity of resisting various shallow and deep fungi. Compared with the existing antifungal drugs in clinical application, the pyrazolopyrimidine compound has the advantages of high efficiency, low toxicity and wide antifungal spectrum and can be used for preparation of antifungal drugs.
Description
Technical field
The present invention relates to a kind of chemical compound and use, specifically, is the application about a kind of throat azoles miazines chemical compound.
Background technology
The position that fungal infectious disease is invaded human body according to fungus is divided into 4 classes: superficial fungi disease, dermatomycosis, subcutaneous mycosis and systemic mycoses; The former two is collectively referred to as superficial mycosis, and the latter two are called again deep mycosis.Fungal infectious disease is divided into following several according to the fungal infection difference: candida albicans bacterium infectious disease, Candida parapsilosis bacterium infectious disease, the Candida glabrata infectious disease, the infection by Cryptococcus neoformans disease, Gypsum Fibrosum shape sporidiole bacteria infectious disease, the trichophyton infectious disease, the aspergillus fumigatus infection disease.
In recent years, extensive use along with broad ectrum antibiotic, corticosteroid and immunosuppressant, the popularization of advanced Clinics such as organ transplantation etc., AIDS's is popular, and the impact of tumor Radiotherapy chemotherapy, cause fungal infection particularly deep fungal infection significantly rise, deep fungal infection has now become the major disease main causes of death such as acquired immune deficiency syndrome (AIDS) and tumor.
The nitrogen azole compounds of having reported at present and having commonly used clinically has ketoconazole (Ketoconazole, KCZ), fluconazol (Fluconazole, FCZ), voriconazole (Voriconazole, VCZ), itraconazole (Itraconazole, ICZ), amphotericin B (Amphotericin B, AMB) etc., but these chemical compounds still exist, and above-mentioned toxic and side effects is large, narrow antimicrobial spectrum, easily produce the defective such as drug resistance, for example bring into play the required dosage of drug effect larger, thereby can produce larger toxic and side effects to human body.。
Summary of the invention
The application that provides a kind of throat azoles miazines chemical compound to catch trichophyton is provided for deficiency of the prior art.
For achieving the above object, the technical scheme that the present invention takes is: the application of a kind of throat azoles miazines chemical compound in preparation trichophyton infectious disease medicament, described throat azoles miazines chemical compound is N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3, the 4-diamidogen.
The invention has the advantages that: chemical compound of the present invention has good antifungal activity to various superficial parts and deep fungal, compares with the antifungal drug of existing clinical practice, has the advantages such as efficient, hypotoxicity, anti-fungus spectra be wide, can be used for preparing antifungal drug.
The specific embodiment
The below elaborates to the specific embodiment provided by the invention.
Embodiment 1
The below elaborates to the specific embodiment provided by the invention.
(1) experimental technique: adopt conventional In Vitro Bacteriostasis experimental technique (to see for details: Antimicrob Agents Chemother 1995,39 (5): 1169)
1. materials and methods
(1) testing compound of the present invention: N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3, the 4-diamidogen
The experiment of particular compound:
Buy the Tocris Bioscience(U.S., Ellisville) ready-made chemical compound (Cat. No. 2731) carries out cytologic experiment, and specifying information is as follows:
CGP57380，CAS?number：522629-08-9
Molecular weight: 244.23
Chemical name: N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3, the 4-diamidogen (N3-(4-Fluorophenyl)-1H-pyrazolo-[3,4-d] pyrimidine-3,4-diamine)
Molecular formula: C
11H
9FN
6
Experimental strain is as follows:
This experiment has selected following 8 kinds of common human body cause illness's standard fungal bacterial strains as screening object:
Table 1 antifungal activity in-vitro screening strain subject
| Strain name | Species | Strain number |
| The candida albicans bacterium | Candida albicans | Y0109 |
| The candida albicans bacterium | Candida albicans | SC5314 |
| The Candida parapsilosis bacterium | Candida parapsilosis | ATCC 22019 |
| Candida glabrata | Candida glabrata | 537 |
| Neogenesis cryptococcus | cryptococcus neoformans | 32609 |
| Gypsum Fibrosum shape sporidiole bacteria | Microsporum gypseum | Cmccfmza |
| Trichophyton | Trichophyton rubrum | Cmccftla |
| Aspergillus fumigatus | Aspergillus fumigatus | 07544 |
(2) test method
The bacteria suspension preparation: above-mentioned fungus was cultivated 16 hours through 35 ℃ of YEPD fluid mediums, and twice activation with the blood cell counting plate counting, adjusted bacteria concentration to 1 * 10 with the RPM1640 fluid medium
4～1 * 10
5Individual/mL.
Medicinal liquid preparation: get testing compound of the present invention and be dissolved in dimethyl sulfoxine, be made into the medicine storage liquid of 8.0mg/mL, be diluted to 640 μ g/mL with RPM1640 before the experiment.
Inoculation: get drug sensitive plate, add RPMI RPMI-1640 200 μ l in No. 1 hole of every row, make blank; No. 12 the hole adds bacterium liquid 200 μ l to be measured, makes negative control; 2 ~ No. 11 holes of the every row of drug sensitive plate add respectively bacterium liquid 180 μ l, and fully mixing makes the final drug level in each hole be respectively 64,32,16,8,4,2,1,0.5,0.25 and 0.125 μ g/ml, and DMSO content all is lower than 1% in each hole; No. 12 the hole does not contain medicine, makes positive control.Control drug is fluconazol (FCZ), itraconazole (ICZ), voriconazole (VCZ), ketoconazole (KCZ), terbinafine (TBR), amphotericin B (AMB).
Cultivate and detect: establishing positive control hole optical density value (OD value) is 100%, is lower than 80% lowest concentration of drug take optical density value than positive control hole and is minimal inhibitory concentration value (MIC
80).
(2) experimental result
The In Vitro Bacteriostasis experimental result sees Table 2.
Table 2 the compounds of this invention is to common pathomycete external activity (MIC, μ g/ml)
| Chemical compound | Y0109 | SC5314 | Nearly flat 22019 | New hidden 32609 | Smooth 537 | Cigarette song 07544 | Red hair Cmccftla | The little Cmccfmza of stone |
| c1 | 8 | 8 | 2 | 1 | 1 | >64 | >64 | >64 |
| ICZ | 8 | 4 | 8 | 4 | 8 | 8 | 2 | 2 |
| TRB | 64 | 32 | 1 | 1 | 4 | 0.5 | 0.125 | 0.0625 |
| KCZ | 0.25 | 0.25 | 0.5 | 0.125 | 0.5 | 8 | 1 | 1 |
| VCZ | 0.03125 | 0.0625 | 0.03125 | 0.0156 | 0.03125 | 0.25 | 0.03125 | 0.125 |
| AMB | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 0.125 |
| FCZ | 0.5 | 0.5 | 1 | 1 | 1 | >64 | 8 | 8 |
Annotate: KCZ. ketoconazole, FCZ. fluconazol, VCZ. Wo Likang azoles, ICZ. itraconazole, TRB. terbinafine, AMB amphotericin
Above-mentioned experimental result shows that chemical compound of the present invention has good antifungal activity, and chemical compound all far is better than fluconazol to the vitro inhibition activity of selected fungus, illustrates that the compounds of this invention can be used for preparing the medicine of anti-fungal infection.
The above only is preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; can also make some improvement and replenish, these improvement and replenish and also should be considered as protection scope of the present invention.
Claims (1)
1. the application of throat azoles miazines chemical compound in preparation trichophyton infectious disease medicament, described throat azoles miazines chemical compound is N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3, the 4-diamidogen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310332524.6A CN103356626B (en) | 2013-08-02 | 2013-08-02 | Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310332524.6A CN103356626B (en) | 2013-08-02 | 2013-08-02 | Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103356626A true CN103356626A (en) | 2013-10-23 |
| CN103356626B CN103356626B (en) | 2015-01-07 |
Family
ID=49359443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310332524.6A Expired - Fee Related CN103356626B (en) | 2013-08-02 | 2013-08-02 | Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356626B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102869669A (en) * | 2010-02-26 | 2013-01-09 | 贝林格尔.英格海姆国际有限公司 | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
-
2013
- 2013-08-02 CN CN201310332524.6A patent/CN103356626B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102869669A (en) * | 2010-02-26 | 2013-01-09 | 贝林格尔.英格海姆国际有限公司 | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103356626B (en) | 2015-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103536613B (en) | A kind of antifungal pharmaceutical composition | |
| US20150366845A1 (en) | Pharmaceutical composition for diseases caused by pathogenic microorganisms such as aspergillus | |
| CN110769854B (en) | Antifungal agents for use in combination | |
| BR112020002290A2 (en) | methods of treating a fungal infection in an individual in need of it, of preventing a fungal infection in an individual, and of treating infection by vulvovaginal candidiasis (vvc) in an individual in need of it | |
| CN103356628B (en) | Use of pyrazolopyrimidine compound in pharmacy | |
| CN103356627B (en) | Use of drug in treatment on candida glabrata infected diseases | |
| Khan et al. | Antifungal potential of disulfiram | |
| CN103356625B (en) | Use of pyrazolopyrimidine compound in treatment on candida parapsilosis infected diseases | |
| CN103405439B (en) | Application of pyrimidine compound to preparing antifungal medicines | |
| CN103356626B (en) | Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases | |
| CN103356624B (en) | Use of pyrimidine compound in antifungal drugs | |
| CN103417545B (en) | Application of pyrazolopyrimidine compound in preparing medicines for aspergillus fumigatus infectious diseases | |
| Werbel et al. | Angioinvasive, cutaneous infection due to Colletotrichum siamense in a stem cell transplant recipient: Report and review of prior cases | |
| CN103565794A (en) | Application of 7-hydroxy-4'-methoxyisoflavone in antifungal medicament | |
| CN103585143A (en) | Application of formononetin in preparation of aspergillus fumigatus resistant medicament | |
| CN107812011A (en) | A kind of antimycotic pharmaceutical composition | |
| CN103565791A (en) | Application of formononetin in trichophyton rubrum | |
| CN103565795A (en) | Application of formononetin in antifungal medicaments | |
| CN103565793A (en) | Application of formononetin in antifungal medicaments | |
| CN103565790A (en) | Application of formononetin in cryptococcus neoformans | |
| CN103565792A (en) | Application of formononetin in microsporum gypseum | |
| CN111297856B (en) | Medicinal composition for resisting fungal infection and application thereof | |
| CN103951625A (en) | Piperazine-containing 1,2,3-triazole antifungal compound and preparation method and application thereof | |
| CN106344545B (en) | Application of the cinnaldehydrum in preparing for targeted therapy drug resistance aspergillin infection drug | |
| CN103387548B (en) | 1,2,3-triazole antifungal compounds, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI TENTH PEOPLE'S HOSPITAL Free format text: FORMER OWNER: TAICANG SHENGZHOU BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20141204 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215434 SUZHOU, JIANGSU PROVINCE TO: 200072 PUTUO, SHANGHAI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20141204 Address after: 200072 No. 301, Yanchang Road, Shanghai Applicant after: Shanghai Tenth People's Hospital Address before: 215434 room 20, building 151, middle Town, pontoon bridge, Taicang, Jiangsu, Suzhou Applicant before: Taicang City Shengzhou Biological Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150107 Termination date: 20180802 |